

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - California Institute of Regenerative Medicine and Cancer Research: A promise broken?
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years
- After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations
“We are not just funding research. We are building a trusted community.”
















